Cited by 216Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR

Watanabe, Masaru, Kawaguchi, Tomoya, Isa, Shun-ichi, Ando, Masahiko, Tamiya, Akihiro, Kubo, Akihito, Saka, Hideo, Takeo, Sadanori, Adachi, Hirofumi, Tagawa, Tsutomu, Kakegawa, Seiichi, Yamashita, Motohiro, Kataoka, Kazuhiko, Ichinose, Yukito, Takeuchi, Yukiyasu, Sakamoto, Kazuhiro, Matsumura, Akihide, Koh, Yasuhiro·2015·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-14-2151

Published version of a preprint

Open this paper in CoChat — free account

Abstract

PURPOSE: The resistance to the EGFR tyrosine kinase inhibitors (TKI) is a major concern in non-small cell lung cancer (NSCLC) treatment. T790M mutation in EGFR accounts for nearly 50% of the acquired resistance to EGFR-TKIs. Earlier studies suggested that T790M mutation was also detected in TKI-naïve NSCLCs in a small cohort. Here, we use an ultra-sensitive droplet digital PCR (ddPCR) technique to address the incidence and clinical significance of pretreatment T790M in a larger cohort. EXPERIMENTAL DESIGN: ddPCR was established as follows: wild-type or T790M mutation-containing DNA fragments were cloned into plasmids. Candidate threshold was identified using wild-type plasmid, normal human genomic DNA, and human A549 cell line DNA, which expresses wild type. Surgically resected tumor tissues from 373 NSCLC patients with EGFR-activating mutations were then examined for the presence of T790M using ddPCR. RESULTS: Our data revealed a linear performance for this ddPCR method (R(2) = 0.998) with an analytical sensitivity of approximately 0.001%. The overall incidence of the pretreatment T790M mutation was 79.9% (298/373), and the frequency ranged from 0.009% to 26.9%. The T790M mutation was detected more frequently in patients with a larger tumor size (P = 0.019) and those with common EGFR-activating mutations (P = 0.022), as compared with the others. CONCLUSIONS: The ultra-sensitive ddPCR assay revealed that pretreatment T790M was found in the majority of NSCLC patients with EGFR-activating mutations. ddPCR should be utilized for detailed assessment of the impact of the low frequency pretreatment T790M mutation on treatment with EGFR-TKIs.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-2151

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Self-citation
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373

Show all 42 references

Sorted by citations

Understanding and targeting resistance mechanisms in NSCLC
Rotow, J. K., & Bivona, T. G. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.84 · Cited by 997
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Jiao, Q., Bi, L., Ren, Y., Song, S., Wang, Q., & Wang, Y. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0801-5 · Cited by 414
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
Remón, J., Steuer, C. E., Ramalingam, S. S., & Felip, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx704 · Cited by 332
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
Tan, D. S. W., Yom, S. S., Tsao, M. S., Pass, H. I., Kelly, K., Peled, N., Yung, R. C., Wistuba, I. I., Yatabe, Y., Unger, M., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.008 · Cited by 201
Current and Emerging Applications of Droplet Digital PCR in Oncology
López, S. O., García‐Arranz, M., & García‐Olmo, D. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0278-8 · Cited by 208
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial
Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Massutí, B., Palmero, R., Aix, S. P., Carcereny, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30129-7 · Cited by 182
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Fois, S. S., Paliogiannis, P., Zinellu, A., Fois, A. G., Cossu, A., & Palmieri, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020612 · Cited by 200
Droplet-based microfluidics in biomedical applications
Amirifar, L., Besanjideh, M., Nasiri, R., Shamloo, A., Nasrollahi, F., de Barros, N. R., Davoodi, E., Erdem, A., Mahmoodi, M., Hosseini, V., et al. (2021) · Biofabrication · doi:10.1088/1758-5090/ac39a9 · Cited by 187
Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients
Sorber, L., Zwaenepoel, K., Deschoolmeester, V., Schil, P. E. V., van Meerbeeck, J. P., Lardon, F., Rolfo, C. D., & Pauwels, P. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.026 · Cited by 159
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156
Three-color crystal digital PCR
Madic, J., Zocevic, A., Senlis, V., Fradet, E., Andre, B., Muller, S., Dangla, R., & Droniou, M. (2016) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2016.10.002 · Cited by 150
Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
Metibemu, D. S., Akinloye, O. A., Akamo, A. J., Ojo, D. A., Okeowo, T. O., & Omotuyi, O. I. (2019) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-019-0035-0 · Cited by 154
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 143
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures
Lee, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.001 · Cited by 142
Cytomegalovirus viral load within blood increases markedly in healthy people over the age of 70 years
Parry, H. M., Zuo, J., Frumento, G., Mirajkar, N., Inman, C., Edwards, E., Griffiths, M., Pratt, G., & Moss, P. (2016) · Immunity & Ageing · doi:10.1186/s12979-015-0056-6 · Cited by 125
EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.06 · Cited by 131
Droplet-Based Digital PCR
Perkins, G., Lu, H., Garlan, F., & Taly, V. (2016) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.10.001 · Cited by 114
Droplet microfluidics for high‐sensitivity and high‐throughput detection and screening of disease biomarkers
Kaushik, A. M., Hsieh, K., & Wang, T. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1522 · Cited by 105
Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer
Watanabe, F., Suzuki, K., Tamaki, S., Abe, I., Endo, Y., Takayama, Y., Ishikawa, H., Kakizawa, N., Saito, M., Futsuhara, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0227366 · Cited by 100
Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations
Zonta, E., Garlan, F., Pécuchet, N., Perez‐Toralla, K., Caën, O., Milbury, C. A., Didelot, A., Fabre, E., Blons, H., Laurent‐Puig, P., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159094 · Cited by 97
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Monica, S. L., Cretella, D., Bonelli, M. A., Fumarola, C., Cavazzoni, A., Digiacomo, G., Flammini, L., Barocelli, E., Minari, R., Naldi, N., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0653-7 · Cited by 82
Beyond the Blood: CSF-Derived cfDNA for Diagnosis and Characterization of CNS Tumors
McEwen, A. E., Leary, S. E. S., & Lockwood, C. M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00045 · Cited by 81
Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma
Xu, T., Kang, X., You, X., Dai, L. X., Tian, D., Yan, W., Yang, Y., Xiong, H., Liang, Z., Zhao, G., et al. (2017) · Theranostics · doi:10.7150/thno.16558 · Cited by 82
Droplet digital PCR applications in the tuberculosis world
Nyaruaba, R., Mwaliko, C., Kering, K., & Wei, H. (2019) · Tuberculosis · doi:10.1016/j.tube.2019.07.001 · Cited by 80
Blood-based tumor biomarkers in lung cancer for detection and treatment
Mamdani, H. M., Ahmed, S. S., Armstrong, S. A., Mok, T. S. K., & Jalal, S. I. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.09.03 · Cited by 75
Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)
Takahama, T., Sakai, K., Takeda, M., Azuma, K., Hida, T., Hirabayashi, M., Oguri, T., Tanaka, H., Ebi, N., Sawa, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11303 · Cited by 73
The safety and efficacy of osimertinib for the treatment ofEGFRT790M mutation positive non-small-cell lung cancer
Gao, X. Y., Le, X., & Costa, D. B. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1162103 · Cited by 72
Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
Chen, M., Xu, Y., Zhao, J., Zhong, W., Zhang, L., Bi, Y., & Wang, M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.023 · Cited by 69
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis
Chen, L.-Y., Molina-Vila, M. A., Ruan, S.-Y., Su, K.-Y., Liao, W.-Y., Yu, K.-L., Ho, C.-C., Shih, J.-Y., Yu, C.-J., Yang, J. C.-H., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.01.019 · Cited by 67
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.
Bordi, P., Re, M. D., Danesi, R., & Tiseo, M. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.08.09 · Cited by 66
High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients
Cho, S., Park, C., Na, D., Han, J. Y., Lee, J. L., Park, O.-K., Zhang, C., Sung, C. O., Moon, H. E., Kim, Y., et al. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.9 · Cited by 66
Selective multiplexed enrichment for the detection and quantitation of low-fraction DNA variants via low-depth sequencing
Song, P., Chen, S. X., Yan, Y. H., Pinto, A., Cheng, L. Y., Dai, P., Patel, A. A., & Zhang, D. Y. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00713-0 · Cited by 68
Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
Noronha, V., Rajendra, A., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_51_19 · Cited by 64
Detection of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma using droplet digital polymerase chain reaction
Biron, V. L., Kostiuk, M. A., Isaac, A., Puttagunta, L., O’Connell, D. A., Harris, J. R., Côté, D. W. J., & Seikaly, H. R. (2016) · Cancer · doi:10.1002/cncr.29976 · Cited by 63
Ultraspecific and Amplification-Free Quantification of Mutant DNA by Single-Molecule Kinetic Fingerprinting
Hayward, S. L., Lund, P. E., Kang, Q., Johnson-Buck, A. E., Tewari, M., & Walter, N. G. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b06685 · Cited by 60
Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases
Huang, R., Xu, X. L., Li, D., Chen, K., Zhan, Q., Ge, M., Zhou, X., Liang, X., & Guan, M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00645-5 · Cited by 62
Principles of digital PCR and its applications in current obstetrical and gynecological diseases.
Mao, X., Liu, C., Tong, H., Chen, Y., & Liu, K. (2019) · Europe PMC (PubMed Central) · Cited by 61
A Self-Priming Digital Polymerase Chain Reaction Chip for Multiplex Genetic Analysis
Yin, J., Zou, Z., Yin, F., Liang, H., Hu, Z., Fang, W., Lv, S., Zhang, T., Wang, B., & Mu, Y. (2020) · ACS Nano · doi:10.1021/acsnano.0c04177 · Cited by 60
Genomic mosaicism in paternal sperm and multiple parental tissues in a Dravet syndrome cohort
Yang, X., Liu, A., Xu, X., Yang, X., Zeng, Q., Ye, A. Y., Yu, Z., Wang, S., Huang, A. Y., Wu, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15814-7 · Cited by 59
Positive EGFR mutation status is a risk of recurrence in pN0–1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis
Ito, M., Miyata, Y., Tsutani, Y., Ito, H., Nakayama, H., Imai, K., Ikeda, N., & Okada, M. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.01.018 · Cited by 58
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to AssessEGFRMutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors
Seki, Y., Fujiwara, Y., Kohno, T., Takai, E., Sunami, K., Goto, Y., Horinouchi, H., Kanda, S., Nokihara, H., WATANABE, S.-I. I., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0288 · Cited by 57
High throughput single cell analysis of mitochondrial heteroplasmy in mitochondrial diseases
Maeda, R., Kami, D., Maeda, H., Shikuma, A., & Gojo, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-67686-z · Cited by 57
Pathologists and liquid biopsies: to be or not to be?
Hofman, P. M., & Popper, H. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-2004-z · Cited by 55
Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma
Alcaide, M., Yu, S., Bushell, K. R., Fornika, D., Nielsen, J. S., Nelson, B. H., Mann, K. K., Assouline, S. E., Johnson, N. A., & Morin, R. D. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255315 · Cited by 54
Application of Digital PCR in Detecting Human Diseases Associated Gene Mutation
Yu, T., Shen, S., Jiang, H., & Chen, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000484035 · Cited by 54
From single-molecule detection to next-generation sequencing: microfluidic droplets for high-throughput nucleic acid analysis
Ding, Y., Choo, J., & deMello, A. J. (2017) · Microfluidics and Nanofluidics · doi:10.1007/s10404-017-1889-4 · Cited by 52
Role of Osimertinib in the Treatment of EGFR-Mutation Positive Non-Small-Cell Lung Cancer
Carlisle, J. W., & Ramalingam, S. S. (2019) · Future Oncology · doi:10.2217/fon-2018-0626 · Cited by 50
Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
Suda, K., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1355243 · Cited by 49
Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR
Zhang, Y., Xu, Y., Zhong, W., Zhao, J., Chen, M., Zhang, L., Li, L., & Wang, M. (2016) · Oncotarget · doi:10.18632/oncotarget.14390 · Cited by 49
The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing
Denis, J. A., Guillerm, E., Coulet, F., Larsen, A. K., & Lacorte, J. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0287-7 · Cited by 50
Tumor-educated platelet as liquid biopsy in lung cancer patients
Liu, L., Lin, F., Ma, X., Chen, Z., & Yu, J. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102863 · Cited by 46
Confirming putative variants at ≤ 5% allele frequency using allele enrichment and Sanger sequencing
Yan, Y. H., Chen, S. X., Cheng, L. Y., Rodriguez, A. Y., Tang, R., Cabrera, K., & Zhang, D. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-91142-1 · Cited by 49
Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.
Costa, D. B., & Kobayashi, S. S. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.05.05 · Cited by 46
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications
Juan, Ó., & Popat, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016687262 · Cited by 43
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
Zhu, C., Zhuang, W., Chen, L., Yang, W., & Ou, W. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.09 · Cited by 46
Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer
Hidaka, N., Iwama, E., Kubo, N., Harada, T., Miyawaki, K., Tanaka, K., Okamoto, I., Baba, E., Akashi, K., Sasaki, H., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.019 · Cited by 44
Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
Li, X., & Zhou, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19007 · Cited by 43
Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter
Watanabe, M., Kenmotsu, H., Ko, R., Wakuda, K., Ono, A., Imai, H., Taira, T., Naito, T., Murakami, H., Abe, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13692 · Cited by 42
Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value
Alegre, E., Fusco, J. P., Restituto, P., Salas‐Benito, D., Rodriguez-Ruiz, M. E., Andueza, M. P., Pajares, M. J., Patiño‐García, A., Pı́o, R., Lozano, M. D., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-5282-9 · Cited by 40
Evaluation of a fast and fully automated platform to diagnose EGFR and KRAS mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day
Lambros, L., Caumont, C., Guibourg, B., Barel, F., Quintin‐Roué, I., Marcorelles, P., Merlio, J., & Uguen, A. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-204202 · Cited by 42
Development of a sensitive and reliable droplet digital PCR assay for the detection of ‘Candidatus Liberibacter asiaticus’
Zhong, X. Z., Xue-lu, L. I. U., Lou, B., Zhou, C., & Wang, X. (2018) · Journal of Integrative Agriculture · doi:10.1016/s2095-3119(17)61815-x · Cited by 40
Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma
Zhou, J., Huang, A., & Yang, X. (2016) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-016-9801-0 · Cited by 42
Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non–Small Cell Lung Carcinoma
Mellert, H. S., Foreman, T. M., Jackson, L. P., Maar, D., Thurston, S., Koch, K., Weaver, A., Cooper, S., Dupuis, N., Sathyanarayana, U. G., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.11.004 · Cited by 37
Epidermal growth factor receptor ( EGFR ) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non‐small cell lung cancer progression during first‐generation tyrosine kinase inhibitor therapy: a prospective observational study
Zhang, S., Zhu, L., Xia, B., Chen, E., Zhao, Q., Zhang, X., Chen, X., Chen, X., & Ma, S. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0303-2 · Cited by 38
Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs
Vendrell, J. A., Mazières, J., Senal, R., Rouquette, I., Quantin, X., Pujol, J.-L., Roch, B., Bouidioua, A., Godreuil, S., Coyaud, É., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2683 · Cited by 40
Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer
Lin, C., Huang, W.-L., Fang, W., Su, W., & Wong, D. T. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1094379 · Cited by 37
Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study
Garcia, J., Dusserre, E., Cheynet, V., Bringuier, P. P., Brengel‐Pesce, K., Wozny, A., Rodriguez‐Lafrasse, C., Freyer, G., Brevet, M., Payen, L. F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21256 · Cited by 36
Monitoring circulating tumor DNA revealed dynamic changes inKRASstatus in patients with metastatic colorectal cancer
Takayama, Y., Suzuki, K., Muto, Y., Ichida, K., Fukui, T., Kakizawa, N., Ishikawa, H., Watanabe, F., Hasegawa, F., Saito, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25309 · Cited by 38
The liquid biopsy in lung cancer
Ansari, J., Yun, J. W., Kompelli, A. R., Moufarrej, Y. E., Alexander, J. S., Herrera, G. A., & Shackelford, R. E. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.127 · Cited by 37
Ultrasensitive detection of oncogenic human papillomavirus in oropharyngeal tissue swabs
Isaac, A., Kostiuk, M. A., Zhang, H., Lindsay, C., Makki, F. M., O’Connell, D. A., Harris, J. R., Côté, D. W. J., Seikaly, H. R., & Biron, V. L. (2017) · Journal of Otolaryngology - Head and Neck Surgery · doi:10.1186/s40463-016-0177-8 · Cited by 36
Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance
Xue, Y., Hou, S., Ji, H., & Han, X. (2016) · Protein & Cell · doi:10.1007/s13238-016-0330-1 · Cited by 35
Circulating Tumor Cells and DNA for Real-Time EGFR Detection and Monitoring of Non-Small-Cell Lung Cancer
He, J., Wei, T., & Jing-ping, M. (2017) · Future Oncology · doi:10.2217/fon-2016-0427 · Cited by 36
Microfluidic flow cytometry for blood-based biomarker analysis
Zhang, Y., Zhao, Y., Cole, T., Zheng, J., Bayinqiaoge, B., Guo, J., & Tang, S. (2022) · The Analyst · doi:10.1039/d2an00283c · Cited by 36
Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment
Izumo, T., Matsumoto, Y., Chavez, C., & Tsuchida, T. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0268-3 · Cited by 35
Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer
Jovelet, C., Madic, J., Remón, J., Honoré, A., Girard, R., Rouleau, É., André, B., Besse, B., Droniou, M., & Lacroix, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183319 · Cited by 33
AZD9291 in EGFR -Mutant Advanced Non-Small-Cell Lung Cancer Patients
Remon, J., & Planchard, D. (2015) · Future Oncology · doi:10.2217/fon.15.250 · Cited by 33
Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations
Masago, K., Fujita, S., Muraki, M., Hata, A., Okuda, C., Otsuka, K., Kaji, R., Takeshita, J., Kato, R., Katakami, N., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1925-2 · Cited by 33
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
Suda, K., Bunn, P. A., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.003 · Cited by 33
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
Poels, K. E., Schoenfeld, A. J., Makhnin, A., Tobi, Y. Y., Wang, Y., Cabanos, H. F., Chakrabarti, S., Shi, M., Napoli, C., McDonald, T. O., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23912-4 · Cited by 32
Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients
Zhu, Y.-J., Zhang, H.-B., Liu, Y., Zhang, F., Zhu, Y., Li, Y., Bai, J., Liu, L., Qu, Y., Qu, X., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.005 · Cited by 33
Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease
Wei, Z., Shah, N., Deng, C., Xiao, X., Zhong, T., & Li, X. (2016) · SpringerPlus · doi:10.1186/s40064-016-2141-5 · Cited by 32
Advances of exosome isolation techniques in lung cancer
Mahgoub, E. O., Razmara, E., Bitaraf, A., Norouzi, F.-S., Montazeri, M., Andouhjerdi, R. B., Falahati, M., Cheng, K., Haik, Y., Hasan, A., et al. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05715-w · Cited by 32
Detection and Diagnostic Utilization of Cellular and Cell-Free Tumor DNA
Dudley, J. C., & Diehn, M. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032604 · Cited by 31
Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
Ntzifa, A., Kotsakis, A. P., Georgoulias, V., & Lianidou, E. S. (2021) · Cancers · doi:10.3390/cancers13112736 · Cited by 32
Agarose-Droplet-Based Digital LAMP Assay for Counting Virus DNA in Single-Particle ICP-MS
Yin, X., Chen, B., He, M., & Hu, B. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c00427 · Cited by 32
Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma
Condello, V., Macerola, E., Ugolini, C., Napoli, L. D., Romei, C., Materazzi, G., Elisei, R., & Basolo, F. (2018) · Head & Neck · doi:10.1002/hed.25155 · Cited by 32
Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients
Qian, Y., Huang, F., Zhang, M., Ji, H., Wu, S., Zhao, Y., Zhang, C., Wu, J., Wang, B., Pan, B., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6712 · Cited by 31
Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions
Ivanov, M. V., Лактионов, К. К., Breder, V. V., Chernenko, P., Новикова, Е. И., Телышева, Е. Н., Musienko, S. V., Baranova, A. V., & Mileyko, V. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1125-8 · Cited by 30
Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
Tsubata, Y., Tanino, R., & Isobe, T. (2021) · Cells · doi:10.3390/cells10113192 · Cited by 31
A comparative study of EGFR oncogenic mutations in matching tissue and plasma samples from patients with advanced non-small cell lung carcinoma
Chai, X., Ren, P., Wei, B., Ma, J., Mai, L., Cram, D. S., Yongping, S., & Guo, Y. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.04.003 · Cited by 27
Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma
Wang, Z., Cheng, G., Han, X., Mu, X., Zhang, Y., Cui, D., Liu, C., Zhang, L., Fan, Z., Ma, L., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.09.008 · Cited by 27
Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review
Chen, X., Wang, L., & Lou, J. (2020) · Medical Science Monitor · doi:10.12659/msm.921040 · Cited by 28
BEAMing LAMP: single-molecule capture and on-bead isothermal amplification for digital detection of hepatitis C virus in plasma
Chen, J., Xu, X., Huang, Z., Luo, Y., Tang, L., & Jiang, J. (2017) · Chemical Communications · doi:10.1039/c7cc08403j · Cited by 26
High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation
Tian, P., Wang, Y., Wang, W., Li, Y., Wang, K., Cheng, X., Tang, Y., Han‐Zhang, H., Ye, J., Chuai, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.08.014 · Cited by 25
Selecting short length nucleic acids localized in exosomes improves plasma EGFR mutation detection in NSCLC patients
Kim, Y., Shin, S., Kim, B., & Lee, K. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0978-8 · Cited by 27
IDH1 mutation detection by droplet digital PCR in glioma
Wang, J., Zhao, Y.-Y., Li, J.-F., Guo, C., Chen, F.-R., Su, H.-K., Zhao, H., Long, Y., Shao, J., To, S. S. T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5630 · Cited by 25
Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits
Alcaide, M., Yu, S. L., Davidson, J., Albuquerque, M., Bushell, K., Fornika, D., Arthur, S., Grande, B., McNamara, S., du Tertre, M. C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10269-2 · Cited by 23
Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays
Jiang, X., Liu, W., Zhu, X., & Xu, X. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10259 · Cited by 26
Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer
Kim, B., Kim, Y., Shin, S., Lee, S., Choi, Y., & Lee, K. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02504-2 · Cited by 26
Evaluation of digital PCR for detecting low-level EGFR mutations in advanced lung adenocarcinoma patients: a cross-platform comparison study
Gu, J., Zang, W., Liu, B., Li, L., Huang, L., Li, S., Rao, G., Yu, Y., & Zhou, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.18866 · Cited by 24

Authors: Watanabe, M., Kawaguchi, T., Isa, S.-I., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., Kakegawa, S., Yamashita, M., Kataoka, K., Ichinose, Y., Takeuchi, Y., Sakamoto, K., Matsumura, A., & Koh, Y.
Affiliations: Wakayama Medical University (JP)
Osaka City University (JP)
NHO Kinki Chuo Chest Medical Center (JP)
Nagoya University Hospital (JP)
Aichi Medical University (JP)
National Hospital Organization (JP)
National Kyushu Medical Center (JP)
Sapporo National Hospital (JP)
Nagasaki Medical Center (JP)
Shikoku Cancer Center (JP)
Iwakuni Medical Center (JP)
National Hospital Organization Kyushu Cancer Center (JP)
Toneyama National Hospital (JP)
National Hospital Organization Yokohama Medical Center (JP)
Corresponding author: Koh, Yasuhiro
ORCID: Watanabe, Masaru
Kawaguchi, Tomoya
Ando, Masahiko
Tamiya, Akihiro
Kubo, Akihito
Saka, Hideo
Sakamoto, Kazuhiro
Koh, Yasuhiro
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2015-08-01
Volume: 21
Issue: 15
Pages: 3552-3560
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-14-2151
OpenAlex: W2006126363
Cited by: 216
References: 42
Citations by year: 2026: 1 · 2025: 4 · 2024: 3 · 2023: 9 · 2022: 24 · 2021: 19 · 2020: 22 · 2019: 30 · 2018: 19 · 2017: 47 · 2016: 32 · 2015: 6
FWCI: 27.38
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: Japan Society for the Promotion of Science (25460896, 23501314)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: T790M mutation, non-small cell lung cancer, EGFR activating mutations, droplet digital PCR, EGFR tyrosine kinase inhibitors, acquired drug resistance, tumor size, analytical sensitivity
MeSH terms: Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Gene Frequency, Humans, Male, Middle Aged, Mutation, Polymerase Chain Reaction, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Precision Medicine, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks